Uremic hyperlipidemia: the nature of the problem.
Increased triglyceride and reduced HDL cholesterol levels are 2 risk factors for atherosclerosis with a high prevalence in chronic hemodialysis patients. Whether they have the same significance in these patients as in the general population is not known. Nonethless, therapy may be indicated because of the severity of the atherosclerotic disorder. The most appropriate drug, clofibrate, is renally excreted and can be used safely if the dosage is markedly reduced. No data exists in any population that such therapy is beneficial.
D002784:Cholesterol / Q000378:metabolism; D002994:Clofibrate / Q000008:administration & dosage; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology*; D008075:Lipoproteins, HDL / Q000378:metabolism; D006435:Renal Dialysis; D014511:Uremia / Q000150:complications* / Q000378:metabolism
D008075:Lipoproteins, HDL; D002784:Cholesterol; D002994:Clofibrate